<DOC>
	<DOC>NCT00442832</DOC>
	<brief_summary>The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.</brief_summary>
	<brief_title>TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection</brief_title>
	<detailed_description>TD-1792 is compared to vancomycin for the treatment of cSSSI.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections requires at least 7 days of intravenous antibiotic treatment more than 24 hours of antibiotic therapy moderate or severe liver disease severely neutropenic baseline QTc &gt; 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>cSSSI</keyword>
	<keyword>Staph</keyword>
	<keyword>MRSA</keyword>
</DOC>